Objective: To assess the efficiency of nandrolone decanoate (ND) in the control of anemia in elderly male patients on hemodialysis (HD), and to determine its influence on nutritional parameters.
Introduction
Androgens were first used in dialysis during the 1970's for the treatment of chronic renal failure (CRF) anemia as the only alternative to transfusional therapy [1] [2] [3] [4] . Their mechanism of action seems to be related to direct stimulation of renal erythropoietin (EPO) production, with an increased sensitivity of erythroid progenitor cells in the bone marrow to the circulating EPO and an activation of their differentiation to normoblasts [6] [7] [8] [9] [10] . In fact, it has been stated that androgens augment the erythropoietic action of lowdose recombinant human erythropoietin (rHuEPO) in hemodialysis (HD) patients [11] [12] . Some authors point out that androgens may also improve the survival of red cells by modulating their metabolism in a beneficial manner [13, 14] .
With the availability of rHuEPO in the late 80's, treatment with androgens in HD was abandoned. However, recent studies have reconsidered the use of nandrolone decanoate (ND) in uremic patients [6, 12, 15] . A retrospective study in HD patients concluded that the anemia response to ND is related to patient age and ND might be considered as an alternative to rHuEPO in male older than 55 years [16] . In addition to the erythropoietic action, androgens have an anabolic effect and they have been used with good results in malnourished patients on chronic ambulatory peritoneal dialysis [17, 18] .
The aim of the present study is to assess the efficiency of ND in the control of anemia in male patients over 65 years of age on HD, and to analyse its influence on nutritional parameters.
Methods

Patients
Thirty-three patients older than 65 years, and on HD therapy for 2 to 144 months were included in the study. All patients were receiving rHuEPO at the maintenance dose (subcutaneously, three times a week). All patients were clinically stable. No patient had a neoplasm or chronic inflamatory or infectious disease diagnosed during the study period.
Patients were divided into two groups. In 14 male patients rHuEPO (4428 ± 3251 IU/week) was stopped and treatment with ND, 200 mg weekly by intramuscular injection on a nondialysis day, for six months, was initiated (Group A). The rHuEPO was stopped 15 days before the start of ND. The remaining 19 patients (12 males and 7 females) continued on rHuEPO therapy (6026 ± 3903 IU/week) (Group E). Patients were studied over a six month period.
The primary renal disease in Group A was diabetic nephropathy in five patients, chronic glomerulonephritis in four patients, nephrosclerosis in two patients, chronic interstitial nephropathy in two patients and Good-Pasture Syndrome in one patient. The primary renal disease in the Group E was chronic interstitial nephropathy in eight patients, nephrosclerosis in four patients, chronic glomerulonephritis in three patients, diabetic nephropathy in two patients, polycystic kidney disease in one patient and unknown etiology in one patient. No patient was anephric. Clinical and analytical data of both groups are shown in Table 1 .
The patients were dialyzed 4 hours, three times a week with cellulose acetate membrane and bicarbonate dialysate. The dry weight was defined as the lowest postdialysis-tolerated weight level and reevaluated for each patient on a monthly basis. Low mollecular weight heparin was used for anticoagulation. The HD schedule was not modified during the period of study. Levels of serum ferritin were maintained higher than 100 ng/mL by intravenous administration of elemental iron.
Blood samples
Samples of peripheral blood were taken before the first HD session of the week. Hematocrit, hemoglobin concentration, and serum levels of creatinine, total protein, albumin, transferrin, ferritin, glutamicoxaloacetic transaminase, glutamic-pyruvic transaminase, alkaline phosphatase, triglycerides, total cholesterol, high density lipoproteins (HDL) cholesterol and low density lipoproteins (LDL) cholesterol were checked basally and every two months in each study group. Cholesterol and triglycerides were measured enzymatically. In both groups apolipoprotein-A1, apolipoprotein-B and lipoprotein (a) were quantitated basally, and after six months by rate nephelometry. In androgens group serum levels of the prostaticspecific antigen were measured basally, and every three months. KT/V was measured bimonthly. The value considered in every patient was the mean of all KT/V values obtained during the 6 months of therapy for anemia. The dose of dialysis during the 6-month study was similar in both groups.
